Tafamidis + SGLT2 inhibitors

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Humans1

Outcomes

Mortality

downin humans1HR 0.576

1 study

Tafamidis + SGLT2 inhibitors decrease mortality in humans (adjusted HR =0.576, 95% CI:0.334–0.992, p =0.04).
“combination therapy with Tafamidis and an SGLT2i was independently associated with a significantly lower risk of mortality (adjusted HR =0.576, 95% CI:0.334–0.992, p =0.04).”
HumansATTR cardiac amyloidosis3-year follow-upn = 1,211
Combination Therapy with SGLT2 Inhibitors and Tafamidis Improves Outcomes More Than Tafamidis Alone in ATTR Cardiac Amyloidosis
AHA Scientific Sessions 2025 abstract3 Nov 2025

Latest

1 in 12 months

AHA Scientific Sessions 2025 Abstract3 Nov

Combination Therapy with SGLT2 Inhibitors and Tafamidis Improves Outcomes More Than Tafamidis Alone in ATTR Cardiac Amyloidosis

Cohort study of 1,211 peopleSGLT2 inhibitors

Paper

Tafamidis + SGLT2 inhibitors

Outcomes

Latest

Combination Therapy with SGLT2 Inhibitors and Tafamidis Improves Outcomes More Than Tafamidis Alone in ATTR Cardiac Amyloidosis

Related